What is the recommended next-line therapy, including dosing and monitoring, for an adult with advanced hepatocellular carcinoma, Child‑Pugh A liver function and ECOG performance status 0‑1, whose disease has progressed on lenvatinib?

Recommended Next-Line Therapy After Lenvatinib Progression

Following progression on lenvatinib in advanced HCC with Child-Pugh A and ECOG PS 0-1, tyrosine kinase inhibitors (TKIs) such as cabozantinib or regorafenib should be offered as second-line therapy, with cabozantinib preferred due to broader evidence in post-TKI settings. 1

Treatment Selection Algorithm

Primary Options (TKIs)

Cabozantinib is the preferred second-line agent after lenvatinib progression:

• Dosing: 60 mg orally once daily 1
• Rationale: Evaluated specifically in patients intolerant or refractory to prior systemic therapy including TKIs, with demonstrated OS benefit versus placebo 1
• Advantage: No requirement for prior sorafenib tolerance, making it suitable for all post-lenvatinib patients

Regorafenib is an alternative option:

• Dosing: 160 mg orally once daily (3 weeks on, 1 week off)
• Critical caveat: Only appropriate if the patient tolerated at least 400 mg of lenvatinib for ≥20 days during the 28-day period prior to progression 1
• Rationale: Regorafenib and sorafenib have nearly identical molecular structures; data extrapolation from post-sorafenib studies is reasonable for post-lenvatinib settings 1
• Limitation: Should be avoided in patients who were intolerant to lenvatinib due to similar toxicity profiles 1

Alternative Consideration

Ramucirumab may be considered if:

• AFP ≥400 ng/mL at progression 1
• Dosing: 8 mg/kg IV every 2 weeks
• Demonstrated survival benefit in this specific biomarker-selected population 1

Emerging Option (Use with Caution)

Atezolizumab plus bevacizumab may be considered in select patients:

• This represents expert panel consensus opinion extrapolated from first-line data 1
• Only appropriate if no contraindications exist (bleeding risk, autoimmune disease, uncontrolled hypertension)
• Critical requirement: Must maintain Child-Pugh A and ECOG PS 0-1 at progression 2
• Data show 93.4% of patients maintaining these parameters successfully transitioned to subsequent therapy versus only 38.0% who did not 2

Monitoring Requirements

Pre-Treatment Assessment

• Confirm Child-Pugh A status (ideally score of 5 for optimal outcomes) 2
• Verify ECOG PS 0-1
• Check AFP level (guides ramucirumab consideration)
• Assess for portal vein invasion and extrahepatic spread (prognostic factors) 2

On-Treatment Monitoring

For Cabozantinib/Regorafenib:

• Liver function tests every 2 weeks for first 2 months, then monthly 3
• Blood pressure monitoring (hypertension common with TKIs)
• Proteinuria screening (urine dipstick; if ≥2+, obtain 24-hour urine protein)
• Renal function (creatinine, electrolytes)
• Cardiac monitoring if history of cardiac dysfunction
• Hand-foot skin reaction assessment

For Ramucirumab:

• Similar monitoring as TKIs
• Particular attention to bleeding risk given anti-VEGF mechanism

Critical Prognostic Factors at Progression

The following independently predict post-progression survival and should guide treatment intensity 2:

• ECOG PS 0 (versus 1)
• Child-Pugh A (ideally score 5)
• Absence of portal vein invasion
• AFP <400 ng/mL

Patients maintaining Child-Pugh A and ECOG PS 0-1 at progression achieve median post-progression survival of 14.7 months versus only 2.0 months in those who deteriorate 2.

Important Clinical Considerations

Lenvatinib Continuation Strategy

Recent real-world data suggest continuing lenvatinib beyond progression may offer survival benefits in select patients (median OS 34.4 vs 21.8 months with switch to regorafenib) 4. However, current guidelines recommend switching to alternative TKIs rather than continuation 5, 1. The guideline states that continuation beyond progression may only be considered "if the patient is perceived to be deriving ongoing clinical benefit" 5, which should be interpreted conservatively.

When NOT to Use Specific Agents

Avoid regorafenib if:

• Patient was intolerant to lenvatinib (similar toxicity profile) 1
• Did not tolerate lenvatinib at adequate dose/duration 1

Avoid ICI-based therapy if:

• Child-Pugh B or C (decompensated cirrhosis) 5
• Active autoimmune disease
• Post-transplant setting (risk of organ rejection) 5
• High bleeding risk with bevacizumab component

Dose Modifications

All TKIs require dose reductions for toxicity:

• Cabozantinib: Reduce to 40 mg, then 20 mg daily as needed
• Regorafenib: Similar stepwise reductions
• Withhold for Grade 3+ toxicities until recovery to Grade ≤2, then resume at reduced dose 3

Bottom Line

The treatment pathway after lenvatinib progression prioritizes maintaining liver function and performance status to enable sequential therapy. 5, 2 Cabozantinib represents the most broadly applicable second-line option, while regorafenib requires prior lenvatinib tolerance. The goal is achieving disease control with subsequent therapy, which independently predicts prolonged post-progression survival (16.1 vs 5.0 months) 2.